Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2251052 vs Imipenem-cilastatin in cUTI and Pyelonephritis
NCT01381549Phase 2Terminated
- Sponsor
- GSK
- Start
- Jun 2011
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of epetraborole in complicated urinary tract infection (cUTI) and acute pyelonephritis (3 arms), sponsored by GSK. Primary endpoints: Change From Baseline in Clinical Laboratory Parameters- Albumin and Total Protein, Change From Baseline in Clinical Laboratory Parameters- Creatinine Clearance, Estimated (CCE) and 11 more. Started Jun 2011; status: terminated.
02
Drugs
epetraborole
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on NCT01381549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01381549.